Genomic Health's President and CEO just cashed-in 2,500 options

Kimberly J Popovits, Genomic Health's President and CEO and a director of the company, recently cashed-in 2,500 options. The options were exercised at $2.88, while the sales took place at $34.31 per share, on September 12, 2013. Popovits continues to hold 262,340 shares of the company. Popovits operates out of Redwood City, CA. Some additional info was provided as follows:

These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on February 20, 2013. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. Represents weighted average sale price. Actual sale prices ranged from $34.04 to $34.51. Includes 10,000 restricted stock units awarded January 27, 2011, of which 1/3 of the shares vest on February 15, 2014, and the 1/3 of the shares that vested on each of February 15, 2012 and 2013, net of withholding. Includes 10,000 restricted stock units awarded February 5, 2012, of which 1/3 vest on each of February 15, 2014 and 2015 and the 1/3 of the shares that vested on February 15, 2013, net of withholding. Includes 9,000 restricted stock units awarded July 25, 2013, of which 1/3 of the shares vest on each of February 15, 2014, 2015 and 2016. The option became exercisable as to 25% of the shares on December 2, 2005, and becomes exercisable as to 1/48th of the shares each full month thereafter.

The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here.

To receive a free e-mail notification whenever Genomic Health makes a similar move, sign up!

Other recent filings from the company include the following:

Genomic Health's EVP of R&D just cashed-in 7,000 options - April 16, 2014

   Auto Refresh

Feedback